A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies
Background: Chemotherapy-induced neutropenia is the most common adverse effect of chemotherapy and is often complicated by febrile neutropenia (FN). The objective of this study is to validate a classification of aggressiveness of a chemotherapy regimen and to evaluate its usefulness in a risk predic...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2009-03, Vol.20 (3), p.513-519 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 519 |
|---|---|
| container_issue | 3 |
| container_start_page | 513 |
| container_title | Annals of oncology |
| container_volume | 20 |
| creator | Moreau, M. Klastersky, J. Schwarzbold, A. Muanza, F. Georgala, A. Aoun, M. Loizidou, A. Barette, M. Costantini, S. Delmelle, M. Dubreucq, L. Vekemans, M. Ferrant, A. Bron, D. Paesmans, M. |
| description | Background: Chemotherapy-induced neutropenia is the most common adverse effect of chemotherapy and is often complicated by febrile neutropenia (FN). The objective of this study is to validate a classification of aggressiveness of a chemotherapy regimen and to evaluate its usefulness in a risk prediction model of FN in patients with hematological cancer at the beginning of a chemotherapy cycle. Patients and methods: Two hundred and sixty-six patients were prospectively enrolled and followed during 1053 cycles. Relevant patient informations were collected at the beginning of the first cycle and the number of days of FN were counted in the follow-up [dichotomized (no FN versus ≥1 day of FN)]. Results: Aggressive chemotherapy regimen is the major predictor of FN [odds ratio 5.2 (3.2–8.4)]. The other independent predictors are the underlying disease, an involvement of bone marrow, body surface ≤2 m2, a baseline monocyte count |
| doi_str_mv | 10.1093/annonc/mdn655 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_196667325</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdn655</oup_id><sourcerecordid>1656082441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c524t-13251e45d91e7b1327b48e5695d7745ae7e06e1478d850807b237b266f5dceb73</originalsourceid><addsrcrecordid>eNqFkM2L1TAUxYMoznN06VaCILipk9s0TbscHjpPHHDhB-ImpOntm4xt0klSmPffm6FlXLq45AZ-nHPPIeQ1sA_AWn6hnfPOXEy9q4V4QnYg6rZoWAVPyY61JS-k4NUZeRHjLWOsbsv2OTmDFngLUu7I8ZIe0WHQIzU3OPl0k_f5RKcTjj75e2tsOtFofECaPJ0D9tYkOmAX7IjU4ZKCn9FZTa2jWUEnP_qjNVlw0qM9Ou2MxfiSPBv0GPHV9p6TH58-ft8fiuuvV5_3l9eFEWWVCuClAKxE3wLKLv9kVzWYI4leykpolMhqhEo2fSNYw2RX8jx1PYjeYCf5OXm76s7B3y0Yk7r1S3DZUkFb17XMBhkqVsgEH2PAQc3BTjqcFDD10KpaW1Vrq5l_s4ku3YT9P3qrMQPvNkDHnHwID6HjI1dCyQGAZ-79yvll_q_ndqONCe8fYR3-qBxCCnX49Vt9-QY_JVwd1J7_BU5Qn_M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>196667325</pqid></control><display><type>article</type><title>A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Moreau, M. ; Klastersky, J. ; Schwarzbold, A. ; Muanza, F. ; Georgala, A. ; Aoun, M. ; Loizidou, A. ; Barette, M. ; Costantini, S. ; Delmelle, M. ; Dubreucq, L. ; Vekemans, M. ; Ferrant, A. ; Bron, D. ; Paesmans, M.</creator><creatorcontrib>Moreau, M. ; Klastersky, J. ; Schwarzbold, A. ; Muanza, F. ; Georgala, A. ; Aoun, M. ; Loizidou, A. ; Barette, M. ; Costantini, S. ; Delmelle, M. ; Dubreucq, L. ; Vekemans, M. ; Ferrant, A. ; Bron, D. ; Paesmans, M.</creatorcontrib><description>Background: Chemotherapy-induced neutropenia is the most common adverse effect of chemotherapy and is often complicated by febrile neutropenia (FN). The objective of this study is to validate a classification of aggressiveness of a chemotherapy regimen and to evaluate its usefulness in a risk prediction model of FN in patients with hematological cancer at the beginning of a chemotherapy cycle. Patients and methods: Two hundred and sixty-six patients were prospectively enrolled and followed during 1053 cycles. Relevant patient informations were collected at the beginning of the first cycle and the number of days of FN were counted in the follow-up [dichotomized (no FN versus ≥1 day of FN)]. Results: Aggressive chemotherapy regimen is the major predictor of FN [odds ratio 5.2 (3.2–8.4)]. The other independent predictors are the underlying disease, an involvement of bone marrow, body surface ≤2 m2, a baseline monocyte count <150/μl and the interaction between the first cycle in the same treatment line and a baseline hemoglobin dosage. A rule of prediction of FN was computed with these characteristics: sensitivity 78.6%, specificity 62.3%, positive predictive value 42.7% and negative predictive value 89.1%. Conclusion: Further studies are needed to validate this score.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdn655</identifier><identifier>PMID: 19139177</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Antineoplastic agents ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; chemotherapy ; febrile neutropenia ; Fever - chemically induced ; Fever - complications ; Hematologic and hematopoietic diseases ; Hematologic Neoplasms - drug therapy ; hematological malignancies ; Humans ; Medical sciences ; myelotoxicity score ; Neutropenia - chemically induced ; Neutropenia - complications ; Other diseases. Hematologic involvement in other diseases ; Pharmacology. Drug treatments ; prediction ; Prospective Studies ; risk model ; Sensitivity and Specificity</subject><ispartof>Annals of oncology, 2009-03, Vol.20 (3), p.513-519</ispartof><rights>The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org 2009</rights><rights>2009 INIST-CNRS</rights><rights>The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c524t-13251e45d91e7b1327b48e5695d7745ae7e06e1478d850807b237b266f5dceb73</citedby><cites>FETCH-LOGICAL-c524t-13251e45d91e7b1327b48e5695d7745ae7e06e1478d850807b237b266f5dceb73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21231113$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19139177$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moreau, M.</creatorcontrib><creatorcontrib>Klastersky, J.</creatorcontrib><creatorcontrib>Schwarzbold, A.</creatorcontrib><creatorcontrib>Muanza, F.</creatorcontrib><creatorcontrib>Georgala, A.</creatorcontrib><creatorcontrib>Aoun, M.</creatorcontrib><creatorcontrib>Loizidou, A.</creatorcontrib><creatorcontrib>Barette, M.</creatorcontrib><creatorcontrib>Costantini, S.</creatorcontrib><creatorcontrib>Delmelle, M.</creatorcontrib><creatorcontrib>Dubreucq, L.</creatorcontrib><creatorcontrib>Vekemans, M.</creatorcontrib><creatorcontrib>Ferrant, A.</creatorcontrib><creatorcontrib>Bron, D.</creatorcontrib><creatorcontrib>Paesmans, M.</creatorcontrib><title>A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Background: Chemotherapy-induced neutropenia is the most common adverse effect of chemotherapy and is often complicated by febrile neutropenia (FN). The objective of this study is to validate a classification of aggressiveness of a chemotherapy regimen and to evaluate its usefulness in a risk prediction model of FN in patients with hematological cancer at the beginning of a chemotherapy cycle. Patients and methods: Two hundred and sixty-six patients were prospectively enrolled and followed during 1053 cycles. Relevant patient informations were collected at the beginning of the first cycle and the number of days of FN were counted in the follow-up [dichotomized (no FN versus ≥1 day of FN)]. Results: Aggressive chemotherapy regimen is the major predictor of FN [odds ratio 5.2 (3.2–8.4)]. The other independent predictors are the underlying disease, an involvement of bone marrow, body surface ≤2 m2, a baseline monocyte count <150/μl and the interaction between the first cycle in the same treatment line and a baseline hemoglobin dosage. A rule of prediction of FN was computed with these characteristics: sensitivity 78.6%, specificity 62.3%, positive predictive value 42.7% and negative predictive value 89.1%. Conclusion: Further studies are needed to validate this score.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>chemotherapy</subject><subject>febrile neutropenia</subject><subject>Fever - chemically induced</subject><subject>Fever - complications</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematologic Neoplasms - drug therapy</subject><subject>hematological malignancies</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>myelotoxicity score</subject><subject>Neutropenia - chemically induced</subject><subject>Neutropenia - complications</subject><subject>Other diseases. Hematologic involvement in other diseases</subject><subject>Pharmacology. Drug treatments</subject><subject>prediction</subject><subject>Prospective Studies</subject><subject>risk model</subject><subject>Sensitivity and Specificity</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM2L1TAUxYMoznN06VaCILipk9s0TbscHjpPHHDhB-ImpOntm4xt0klSmPffm6FlXLq45AZ-nHPPIeQ1sA_AWn6hnfPOXEy9q4V4QnYg6rZoWAVPyY61JS-k4NUZeRHjLWOsbsv2OTmDFngLUu7I8ZIe0WHQIzU3OPl0k_f5RKcTjj75e2tsOtFofECaPJ0D9tYkOmAX7IjU4ZKCn9FZTa2jWUEnP_qjNVlw0qM9Ou2MxfiSPBv0GPHV9p6TH58-ft8fiuuvV5_3l9eFEWWVCuClAKxE3wLKLv9kVzWYI4leykpolMhqhEo2fSNYw2RX8jx1PYjeYCf5OXm76s7B3y0Yk7r1S3DZUkFb17XMBhkqVsgEH2PAQc3BTjqcFDD10KpaW1Vrq5l_s4ku3YT9P3qrMQPvNkDHnHwID6HjI1dCyQGAZ-79yvll_q_ndqONCe8fYR3-qBxCCnX49Vt9-QY_JVwd1J7_BU5Qn_M</recordid><startdate>20090301</startdate><enddate>20090301</enddate><creator>Moreau, M.</creator><creator>Klastersky, J.</creator><creator>Schwarzbold, A.</creator><creator>Muanza, F.</creator><creator>Georgala, A.</creator><creator>Aoun, M.</creator><creator>Loizidou, A.</creator><creator>Barette, M.</creator><creator>Costantini, S.</creator><creator>Delmelle, M.</creator><creator>Dubreucq, L.</creator><creator>Vekemans, M.</creator><creator>Ferrant, A.</creator><creator>Bron, D.</creator><creator>Paesmans, M.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>20090301</creationdate><title>A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies</title><author>Moreau, M. ; Klastersky, J. ; Schwarzbold, A. ; Muanza, F. ; Georgala, A. ; Aoun, M. ; Loizidou, A. ; Barette, M. ; Costantini, S. ; Delmelle, M. ; Dubreucq, L. ; Vekemans, M. ; Ferrant, A. ; Bron, D. ; Paesmans, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c524t-13251e45d91e7b1327b48e5695d7745ae7e06e1478d850807b237b266f5dceb73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>chemotherapy</topic><topic>febrile neutropenia</topic><topic>Fever - chemically induced</topic><topic>Fever - complications</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematologic Neoplasms - drug therapy</topic><topic>hematological malignancies</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>myelotoxicity score</topic><topic>Neutropenia - chemically induced</topic><topic>Neutropenia - complications</topic><topic>Other diseases. Hematologic involvement in other diseases</topic><topic>Pharmacology. Drug treatments</topic><topic>prediction</topic><topic>Prospective Studies</topic><topic>risk model</topic><topic>Sensitivity and Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moreau, M.</creatorcontrib><creatorcontrib>Klastersky, J.</creatorcontrib><creatorcontrib>Schwarzbold, A.</creatorcontrib><creatorcontrib>Muanza, F.</creatorcontrib><creatorcontrib>Georgala, A.</creatorcontrib><creatorcontrib>Aoun, M.</creatorcontrib><creatorcontrib>Loizidou, A.</creatorcontrib><creatorcontrib>Barette, M.</creatorcontrib><creatorcontrib>Costantini, S.</creatorcontrib><creatorcontrib>Delmelle, M.</creatorcontrib><creatorcontrib>Dubreucq, L.</creatorcontrib><creatorcontrib>Vekemans, M.</creatorcontrib><creatorcontrib>Ferrant, A.</creatorcontrib><creatorcontrib>Bron, D.</creatorcontrib><creatorcontrib>Paesmans, M.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moreau, M.</au><au>Klastersky, J.</au><au>Schwarzbold, A.</au><au>Muanza, F.</au><au>Georgala, A.</au><au>Aoun, M.</au><au>Loizidou, A.</au><au>Barette, M.</au><au>Costantini, S.</au><au>Delmelle, M.</au><au>Dubreucq, L.</au><au>Vekemans, M.</au><au>Ferrant, A.</au><au>Bron, D.</au><au>Paesmans, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2009-03-01</date><risdate>2009</risdate><volume>20</volume><issue>3</issue><spage>513</spage><epage>519</epage><pages>513-519</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Background: Chemotherapy-induced neutropenia is the most common adverse effect of chemotherapy and is often complicated by febrile neutropenia (FN). The objective of this study is to validate a classification of aggressiveness of a chemotherapy regimen and to evaluate its usefulness in a risk prediction model of FN in patients with hematological cancer at the beginning of a chemotherapy cycle. Patients and methods: Two hundred and sixty-six patients were prospectively enrolled and followed during 1053 cycles. Relevant patient informations were collected at the beginning of the first cycle and the number of days of FN were counted in the follow-up [dichotomized (no FN versus ≥1 day of FN)]. Results: Aggressive chemotherapy regimen is the major predictor of FN [odds ratio 5.2 (3.2–8.4)]. The other independent predictors are the underlying disease, an involvement of bone marrow, body surface ≤2 m2, a baseline monocyte count <150/μl and the interaction between the first cycle in the same treatment line and a baseline hemoglobin dosage. A rule of prediction of FN was computed with these characteristics: sensitivity 78.6%, specificity 62.3%, positive predictive value 42.7% and negative predictive value 89.1%. Conclusion: Further studies are needed to validate this score.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>19139177</pmid><doi>10.1093/annonc/mdn655</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2009-03, Vol.20 (3), p.513-519 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_journals_196667325 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences chemotherapy febrile neutropenia Fever - chemically induced Fever - complications Hematologic and hematopoietic diseases Hematologic Neoplasms - drug therapy hematological malignancies Humans Medical sciences myelotoxicity score Neutropenia - chemically induced Neutropenia - complications Other diseases. Hematologic involvement in other diseases Pharmacology. Drug treatments prediction Prospective Studies risk model Sensitivity and Specificity |
| title | A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A10%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20general%20chemotherapy%20myelotoxicity%20score%20to%20predict%20febrile%20neutropenia%20in%20hematological%20malignancies&rft.jtitle=Annals%20of%20oncology&rft.au=Moreau,%20M.&rft.date=2009-03-01&rft.volume=20&rft.issue=3&rft.spage=513&rft.epage=519&rft.pages=513-519&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdn655&rft_dat=%3Cproquest_cross%3E1656082441%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=196667325&rft_id=info:pmid/19139177&rft_oup_id=10.1093/annonc/mdn655&rfr_iscdi=true |